Table 1. Snapshot of Europe Multiple Sclerosis Drugs Market in Balanced Perspective, 2020-2027 17
Table 2. Growth Rate of World GDP, 2020-2022 21
Table 3. World Health Spending by Region, $ bn, 2013-2020 28
Table 4. Price Comparison of Commonly Used Multiple Sclerosis Medications 31
Table 5. Main Adverse Effects of Multiple Sclerosis Drugs 32
Table 6. Main Product Trends and Market Opportunities in Europe Multiple Sclerosis Drugs Market 33
Table 7. Europe Multiple Sclerosis Drugs Market by Drug Type, 2017-2027, $ mn 41
Table 8. Europe Multiple Sclerosis Drugs Market: Immunomodulators by Drug, 2017-2027, $ mn 44
Table 9. Europe Multiple Sclerosis Drugs Market: Immunosuppressants by Drug, 2017-2027, $ mn 46
Table 10. Europe Multiple Sclerosis Drugs Market by Drug Class, 2017-2027, $ mn 47
Table 11. Europe Multiple Sclerosis Drugs Market by Drug Category, 2017-2027, $ mn 58
Table 12. Europe Multiple Sclerosis Drugs Market by Route of Administration, 2017-2027, $ mn 62
Table 13. Europe Multiple Sclerosis Drugs Market by MS Type, 2017-2027, $ mn 66
Table 14. Europe Multiple Sclerosis Drugs Market by Distribution Channel, 2017-2027, $ mn 72
Table 15. Europe Multiple Sclerosis Drugs Market by Country, 2017-2027, $ mn 79
Table 16. UK Multiple Sclerosis Drugs Market by Drug Type, 2017-2027, $ mn 81
Table 17. UK Multiple Sclerosis Drugs Market by Route of Administration, 2017-2027, $ mn 81
Table 18. UK Multiple Sclerosis Drugs Market by Distribution Channel, 2017-2027, $ mn 81
Table 19. France Multiple Sclerosis Drugs Market by Drug Type, 2017-2027, $ mn 83
Table 20. France Multiple Sclerosis Drugs Market by Route of Administration, 2017-2027, $ mn 83
Table 21. France Multiple Sclerosis Drugs Market by Distribution Channel, 2017-2027, $ mn 83
Table 22. Germany Multiple Sclerosis Drugs Market by Drug Type, 2017-2027, $ mn 85
Table 23. Germany Multiple Sclerosis Drugs Market by Route of Administration, 2017-2027, $ mn 85
Table 24. Germany Multiple Sclerosis Drugs Market by Distribution Channel, 2017-2027, $ mn 85
Table 25. Spain Multiple Sclerosis Drugs Market by Drug Type, 2017-2027, $ mn 87
Table 26. Spain Multiple Sclerosis Drugs Market by Route of Administration, 2017-2027, $ mn 87
Table 27. Spain Multiple Sclerosis Drugs Market by Distribution Channel, 2017-2027, $ mn 87
Table 28. Italy Multiple Sclerosis Drugs Market by Drug Type, 2017-2027, $ mn 89
Table 29. Italy Multiple Sclerosis Drugs Market by Route of Administration, 2017-2027, $ mn 89
Table 30. Italy Multiple Sclerosis Drugs Market by Distribution Channel, 2017-2027, $ mn 89
Table 31. Russia Multiple Sclerosis Drugs Market by Drug Type, 2017-2027, $ mn 91
Table 32. Russia Multiple Sclerosis Drugs Market by Route of Administration, 2017-2027, $ mn 91
Table 33. Russia Multiple Sclerosis Drugs Market by Distribution Channel, 2017-2027, $ mn 91
Table 34. Multiple Sclerosis Drugs Market in Rest of Europe by Country, 2017-2027, $ mn 93
Table 35. Abbvie, Inc.: Company Snapshot 98
Table 36. Abbvie, Inc.: Business Segmentation 98
Table 37. Abbvie, Inc.: Product Portfolio 99
Table 38. Abbvie, Inc.: Revenue, 2017-2019, $ mn 99

LIST OF FIGURE

Figure 1. Research Method Flow Chart 11
Figure 2. Bottom-up Approach and Top-down Approach for Market Estimation 14
Figure 3. Europe Market Forecast in Optimistic, Conservative and Balanced Perspectives, 2020-2027 16
Figure 4. Europe Multiple Sclerosis Drugs Market, 2017-2027, $ mn 19
Figure 5. Impact of COVID-19 on Business 22
Figure 6. Primary Drivers and Impact Factors of Europe Multiple Sclerosis Drugs Market 24
Figure 7. Worldwide Geriatric Population (60 years and above) by Regions, 2015 & 2030, million 27
Figure 8. World Population 65 and Over, % of Total Population, 1950-2060 27
Figure 9. Primary Restraints and Impact Factors of Europe Multiple Sclerosis Drugs Market 29
Figure 10. Investment Opportunity Analysis 34
Figure 11. Porters Fiver Forces Analysis of Europe Multiple Sclerosis Drugs Market 37
Figure 12. Breakdown of Europe Multiple Sclerosis Drugs Market by Drug Type, 2020-2027, % of Revenue 41
Figure 13. Contribution to Europe 2021-2027 Cumulative Revenue by Drug Type, Value ($ mn) and Share (%) 42
Figure 14. Europe Multiple Sclerosis Drugs Market: Immunomodulators, 2017-2027, $ mn 43
Figure 15. Europe Multiple Sclerosis Drugs Market: Immunosuppressants, 2017-2027, $ mn 45
Figure 16. Breakdown of Europe Multiple Sclerosis Drugs Market by Drug Class, 2020-2027, % of Revenue 48
Figure 17. Contribution to Europe 2021-2027 Cumulative Revenue by Drug Class, Value ($ mn) and Share (%) 48
Figure 18. Europe Multiple Sclerosis Drugs Market: Monoclonal Antibodies, 2017-2027, $ mn 49
Figure 19. Europe Multiple Sclerosis Drugs Market: Interferon Beta, 2017-2027, $ mn 50
Figure 20. Europe Multiple Sclerosis Drugs Market: Sphingosine 1 Phosphate Receptor Modulators, 2017-2027, $ mn 51
Figure 21. Europe Multiple Sclerosis Drugs Market: Mixed Polymers, 2017-2027, $ mn 52
Figure 22. Europe Multiple Sclerosis Drugs Market: NF-?B Inhibitor, 2017-2027, $ mn 53
Figure 23. Europe Multiple Sclerosis Drugs Market: Pyrimidine Synthesis Inhibitor, 2017-2027, $ mn 54
Figure 24. Europe Multiple Sclerosis Drugs Market: Corticosteroids, 2017-2027, $ mn 55
Figure 25. Europe Multiple Sclerosis Drugs Market: Adrenocorticotropic Hormone, 2017-2027, $ mn 56
Figure 26. Europe Multiple Sclerosis Drugs Market: Other Drug Classes, 2017-2027, $ mn 57
Figure 27. Breakdown of Europe Multiple Sclerosis Drugs Market by Drug Category, 2020-2027, % of Revenue 58
Figure 28. Contribution to Europe 2021-2027 Cumulative Revenue by Drug Category, Value ($ mn) and Share (%) 59
Figure 29. Europe Multiple Sclerosis Drugs Market: Large-molecule Drugs, 2017-2027, $ mn 60
Figure 30. Europe Multiple Sclerosis Drugs Market: Small-molecule Drugs, 2017-2027, $ mn 61
Figure 31. Breakdown of Europe Multiple Sclerosis Drugs Market by Route of Administration, 2020-2027, % of Revenue 62
Figure 32. Contribution to Europe 2021-2027 Cumulative Revenue by Route of Administration, Value ($ mn) and Share (%) 63
Figure 33. Europe Multiple Sclerosis Drugs Market: Oral Administration, 2017-2027, $ mn 64
Figure 34. Europe Multiple Sclerosis Drugs Market: Parenteral Administration, 2017-2027, $ mn 65
Figure 35. Breakdown of Europe Multiple Sclerosis Drugs Market by MS Type, 2020-2027, % of Revenue 66
Figure 36. Contribution to Europe 2021-2027 Cumulative Revenue by MS Type, Value ($ mn) and Share (%) 67
Figure 37. Europe Multiple Sclerosis Drugs Market: Relapsing-remitting MS (RRMS), 2017-2027, $ mn 68
Figure 38. Europe Multiple Sclerosis Drugs Market: Primary-progressive MS (PPMS), 2017-2027, $ mn 69
Figure 39. Europe Multiple Sclerosis Drugs Market: Secondary-progressive MS (SPMS), 2017-2027, $ mn 70
Figure 40. Europe Multiple Sclerosis Drugs Market: Progressive-relapsing MS (PRMS), 2017-2027, $ mn 71
Figure 41. Breakdown of Europe Multiple Sclerosis Drugs Market by Distribution Channel, 2020-2027, % of Revenue 72
Figure 42. Contribution to Europe 2021-2027 Cumulative Revenue by Distribution Channel, Value ($ mn) and Share (%) 73
Figure 43. Europe Multiple Sclerosis Drugs Market: Hospital Pharmacies, 2017-2027, $ mn 74
Figure 44. Europe Multiple Sclerosis Drugs Market: Retail Pharmacies, 2017-2027, $ mn 75
Figure 45. Europe Multiple Sclerosis Drugs Market: Online Pharmacies, 2017-2027, $ mn 76
Figure 46. Breakdown of European Multiple Sclerosis Drugs Market by Country, 2020 and 2027, % of Revenue 78
Figure 47. Contribution to Europe 2021-2027 Cumulative Revenue by Country, Value ($ mn) and Share (%) 79
Figure 48. Multiple Sclerosis Drugs Market in UK, 2017-2027, $ mn 80
Figure 49. Multiple Sclerosis Drugs Market in France, 2017-2027, $ mn 82
Figure 50. Multiple Sclerosis Drugs Market in Germany, 2017-2027, $ mn 84
Figure 51. Multiple Sclerosis Drugs Market in Spain, 2017-2027, $ mn 86
Figure 52. Multiple Sclerosis Drugs Market in Italy, 2017-2027, $ mn 88
Figure 53. Multiple Sclerosis Drugs Market in Russia, 2017-2027, $ mn 90
Figure 54. Multiple Sclerosis Drugs Market in Rest of Europe, 2017-2027, $ mn 92
Figure 55. Growth Stage of Europe Multiple Sclerosis Drugs Industry over the Forecast Period 94